Rogelio Machuca MD Family Medicine, PLLC. | Las Vegas, NV

Research site

Location

546 North Eastern Avenue Suite 140, Las Vegas, Nevada, United States of America

Site insights

Top conditions

Top treatments

Orforglipron

LY3502970

Astegolimab

Formoterol Fumarate

MK-6024

PF-06865571

Baloxavir Marboxil

BIO89-100

MK-6024-013

Glycopyrronium

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Nara Pagliarulo

Verified by this site

Active trials

9 of 16 total trials

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatit...

Active, not recruiting

Metabolic Dysfunction-associated Steatotic Liver Disease

Non-alcoholic Fatty Liver Disease

Combination Product: Efinopegdutide

Combination Product: Placebo

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants w...

Enrolling

Overweight

Obesity

Drug: Placebo

Drug: Orforglipron

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA th...

Enrolling

COPD (Chronic Obstructive Pulmonary Disease)

Drug: BGF MDI 320/14.4/9.6 μg

Drug: GFF MDI 14.4/9.6 μg

Locations recently updated

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overw...

Enrolling

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with...

Enrolling

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA)

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling

Chronic Obstructive Pulmonary Disease (COPD)

Drug: Astegolimab

Drug: Placebo

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Astegolimab

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts (Pebblestone)

This study consists of two parts: Part A Surveillance and Part B Transmission.The main purpose of Part A is to evaluate the prevalence of pre-dose an...

Enrolling

Influenza

Drug: Baloxavir Marboxil